Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 24, 2020

Study Completion Date

January 24, 2020

Conditions
Parkinson's Disease
Interventions
BIOLOGICAL

VY-AADC01

Neurosurgical delivery of VY-AADC01 to the brain.

Trial Locations (2)

15213

University of Pittsburgh, Pittsburgh

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

University of California, San Francisco

OTHER

collaborator

Veristat, Inc.

OTHER

collaborator

Feinstein Institute for Medical Research

OTHER

collaborator

Oregon Health and Science University

OTHER

collaborator

Voyager Therapeutics

INDUSTRY

lead

Neurocrine Biosciences

INDUSTRY